Absci Corp Total Assets
Absci Corp total assets. Based on the latest financial reports, Absci Corp (ABSI) holds total assets worth $268.92 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Absci Corp for the company's overall valuation and market capitalisation.
Total Assets of Absci Corp (2019–2025)
Total assets of Absci Corp from 2019 to 2025. This chart illustrates how Absci Corp's total assets have evolved over time, based on quarterly financial data. See Absci Corp stock price for real-time trading data and today's change.
Absci Corp - Asset Composition Analysis
Absci Corp Total Assets Breakdown (December 2025)
Absci Corp total assets breakdown as of December 2025. Absci Corp's total assets of $268.92 Million consist of 69.2% current assets and 30.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $41.51 Million | 19.2% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Absci Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore ABSI working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Absci Corp's current assets represent 69.2% of total assets in 2025, a decrease from 70.1% in 2019.
- Cash Position: Cash and equivalents constituted 9.3% of total assets in 2025, down from 67.2% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 19.0% of total assets, an increase from 1.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 19.2% of total assets.
Absci Corp Competitors by Total Assets
Key competitors of Absci Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Absci Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.63 | 4.39 | 9.94 |
| Quick Ratio | 10.63 | 4.39 | 9.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $188.67 Million | $106.08 Million | $270.42 Million |
Absci Corp - Advanced Valuation Insights
This section examines the relationship between Absci Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.74 |
| Latest Market Cap to Assets Ratio | 6.51 |
| Asset Growth Rate (YoY) | 1.3% |
| Total Assets | $216.30 Million |
| Market Capitalization | $1.41 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Absci Corp's assets at a significant premium (6.51x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Absci Corp's assets grew by 1.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Absci Corp (2019–2025)
The table below shows the annual total assets of Absci Corp from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $216.30 Million | +1.26% |
| 2024-12-31 | $213.61 Million | -1.70% |
| 2023-12-31 | $217.30 Million | -32.31% |
| 2022-12-31 | $321.01 Million | -24.68% |
| 2021-12-31 | $426.19 Million | +381.20% |
| 2020-12-31 | $88.57 Million | +354.88% |
| 2019-12-31 | $19.47 Million | -- |
About Absci Corp
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the… Read more